Skip to content
sellNotable cluster of 5

Kenneth Bate sold $3.7M of MDGL

director at MADRIGAL PHARMACEUTICALS, INC.. 10,000 shares at an average of $365.20, traded Aug 15, 2025, filed Aug 15, 2025.

Warning score
60
Value
$3.7M
10,000 shares
Holdings after
2,627
-79% from before
From 52-week low
+83%
low $202.48, close $369.84
From 52-week high
-1%
high $373.46, as of Aug 15, 2025

Score components

  • Role
    Director
    +15
  • Trade size
    $3.7M at market
    +25
  • Share of holdings sold
    Sold 79% of holdings
    +20
  • Cluster
    5 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

MDGLOct 9, 2026 · close 471.75
Since filing Aug 15, 2025: +27.6%SPY +22.6% · excess +4.9%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001210238-25-000005, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Aug 15, 2025MOption exercise
Common Stock
+10,000$16.46$165k12,627Aug 15, 2025
Aug 15, 2025SOpen-market sale
Common Stock
-2,317$363.41$842k10,310Aug 15, 2025
Aug 15, 2025SOpen-market sale
Common Stock
-2,516$364.24$916k7,794Aug 15, 2025
Aug 15, 2025SOpen-market sale
Common Stock
-2,567$365.33$938k5,227Aug 15, 2025
Aug 15, 2025SOpen-market sale
Common Stock
-600$366.14$220k4,627Aug 15, 2025
Aug 15, 2025SOpen-market sale
Common Stock
-1,104$367.63$406k3,523Aug 15, 2025
Aug 15, 2025SOpen-market sale
Common Stock
-896$368.56$330k2,627Aug 15, 2025
Aug 15, 2025MOption exercise
Stock Option (Right to Buy)derivative
-10,000$0.00$00Aug 15, 2025

Related signals

Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
30Weak
MDGLsell10b5-1
MADRIGAL PHARMACEUTICALS, INC.
William John Sibold
President and CEO
$6.2M
11,583 shares
-6%
25Weak
MDGLsell 410b5-1
MADRIGAL PHARMACEUTICALS, INC.
Paul A Friedman
director
$14M
24,800 shares
-12%
20Weak
MDGLsell 410b5-1
MADRIGAL PHARMACEUTICALS, INC.
Rebecca Taub
director
$10M
18,650 shares
-4%
50Moderate
MDGLsell 5
MADRIGAL PHARMACEUTICALS, INC.
William John Sibold
President and CEO
$1.4M
2,400 shares
-2%
37Weak
MDGLsell 510b5-1
MADRIGAL PHARMACEUTICALS, INC.
Mardi Dier
EVP and CFO
$2.4M
4,173 shares
-29%
40Moderate
MDGLsell 410b5-1
MADRIGAL PHARMACEUTICALS, INC.
Carole Huntsman
Chief Commercial Officer
$1.1M
1,958 shares
-16%
30Weak
MDGLsell 310b5-1
MADRIGAL PHARMACEUTICALS, INC.
Richard S Levy
director
$4.4M
8,500 shares
-29%
53Moderate
MDGLsell 2
MADRIGAL PHARMACEUTICALS, INC.
Kenneth Bate
director
$8.0M
16,575 shares
-86%
50Moderate
MDGLsell
MADRIGAL PHARMACEUTICALS, INC.
William John Sibold
President and CEO
$3.2M
7,279 shares
-7%
45Moderate
MDGLsell 510b5-1
MADRIGAL PHARMACEUTICALS, INC.
William John Sibold
President and CEO
$3.0M
7,616 shares
-6%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Kenneth Bate sold $3.7M of MDGL | InsiderTell